PI3K/Akt/mTOR activation by suppression of ELK3 mediates chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting autophagy

Citations

WEB OF SCIENCE

46
Citations

SCOPUS

46

초록

Drug resistance in breast cancer remains a major obstacle of clinical therapy. We found that suppression of ELK3 in the triple negative breast cancer cell line MDA-MB-231 impaired autophagy and led to a hypersensitive response to doxorubicin treatment. In ELK3-knockdown MDA-MB-231 cells (ELK3 KD), autophagy was not activated under starvation conditions, which is a major stimulus of autophagy activation. We revealed that activation of the PI3K/Akt pathway was the main cause of impaired autophagy in ELK3 KD. Our results suggest that targeting ELK3 may be a potential approach to overcome doxorubicin resistance in breast cancer therapeutics. (C) 2016 Published by Elsevier Inc.

키워드

Autophagy; Doxorubicin; ELK3; MDA-MB-231 cell line; PI3K/Akt; ADVANCED SOLID TUMORS; BREAST-CANCER CELLS; PHASE-I TRIAL; HYDROXYCHLOROQUINE; APOPTOSIS; PATHWAY; KINASE; NET; TRANSCRIPTION; TEMOZOLOMIDE
제목
PI3K/Akt/mTOR activation by suppression of ELK3 mediates chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting autophagy
저자
Park, Ji-Hoon; Kim, Keun Pil; Ko, Jeong-Jae; Park, Kyung-Soon
DOI
10.1016/j.bbrc.2016.06.057
발행일
2016-08
유형
Article
저널명
Biochemical and Biophysical Research Communications
권
477
호
2
페이지
277 ~ 282